These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33580245)

  • 1. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study.
    Sun Y; Kim E; Kong CL; Arnold BF; Porco TC; Acharya NR
    Clin Infect Dis; 2021 Sep; 73(6):949-956. PubMed ID: 33580245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR
    Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.
    Izurieta HS; Wu X; Forshee R; Lu Y; Sung HM; Agger PE; Chillarige Y; Link-Gelles R; Lufkin B; Wernecke M; MaCurdy TE; Kelman J; Dooling K
    Clin Infect Dis; 2021 Sep; 73(6):941-948. PubMed ID: 33580242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the effectiveness of zoster vaccine live: A retrospective cohort study using primary care data in the United Kingdom.
    Matthews I; Lu X; Dawson H; Bricout H; O'Hanlon H; Yu E; Nozad B
    Vaccine; 2018 Nov; 36(46):7105-7111. PubMed ID: 30195489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of herpes zoster vaccination in an older United Kingdom population.
    Walker JL; Andrews NJ; Amirthalingam G; Forbes H; Langan SM; Thomas SL
    Vaccine; 2018 Apr; 36(17):2371-2377. PubMed ID: 29555217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.
    Tseng HF; Smith N; Harpaz R; Bialek SR; Sy LS; Jacobsen SJ
    JAMA; 2011 Jan; 305(2):160-6. PubMed ID: 21224457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records.
    Klein NP; Bartlett J; Fireman B; Marks MA; Hansen J; Lewis E; Aukes L; Saddier P
    BMJ; 2023 Nov; 383():e076321. PubMed ID: 37940142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.
    Zhang J; Xie F; Delzell E; Chen L; Winthrop KL; Lewis JD; Saag KG; Baddley JW; Curtis JR
    JAMA; 2012 Jul; 308(1):43-9. PubMed ID: 22760290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.
    Izurieta HS; Wernecke M; Kelman J; Wong S; Forshee R; Pratt D; Lu Y; Sun Q; Jankosky C; Krause P; Worrall C; MaCurdy T; Harpaz R
    Clin Infect Dis; 2017 Mar; 64(6):785-793. PubMed ID: 28362955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.
    Zhang J; Delzell E; Xie F; Baddley JW; Spettell C; McMahan RM; Fernandes J; Chen L; Winthrop K; Curtis JR
    Arthritis Res Ther; 2011; 13(5):R174. PubMed ID: 22024532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
    Zerbo O; Bartlett J; Fireman B; Lewis N; Goddard K; Dooling K; Duffy J; Glanz J; Naleway A; Donahue JG; Klein NP
    Ann Intern Med; 2024 Feb; 177(2):189-195. PubMed ID: 38190712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
    Baxter R; Bartlett J; Fireman B; Marks M; Hansen J; Lewis E; Aukes L; Chen Y; Klein NP; Saddier P
    Am J Epidemiol; 2018 Jan; 187(1):161-169. PubMed ID: 29309521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes Zoster and Postherpetic Neuralgia: Changing Incidence Rates From 1994 to 2018 in the United States.
    Thompson RR; Kong CL; Porco TC; Kim E; Ebert CD; Acharya NR
    Clin Infect Dis; 2021 Nov; 73(9):e3210-e3217. PubMed ID: 32829399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual incidence rates of herpes zoster among an immunocompetent population in the United States.
    Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
    BMC Infect Dis; 2015 Nov; 15():502. PubMed ID: 26546419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients With Inflammatory Bowel Diseases.
    Khan N; Trivedi C; Kavani H; Medvedeva E; Lewis J; Yang YX
    Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1341-1347. PubMed ID: 30326303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
    Drolet M; Zhou Z; Sauvageau C; DeWals P; Gilca V; Amini R; Bénard É; Brisson M
    CMAJ; 2019 Aug; 191(34):E932-E939. PubMed ID: 31451524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.